IN THE CLAIMS:

Please cancel Claims 37 and 50 without prejudice to or disclaimer of the subject matter contained therein.

Please amend Claims 35 and 51, and add new Claims 74-81 to read as follows:

35. (Currently Amended) An isolated ~~A~~ peptide selected from the group consisting of Seq ID No. 17 and Seq ID No. 428 ~~that:~~

~~a) is at least 8 amino acid residues long and is a fragment of a mutant protein arising from a frameshift mutation in the TFG-β-RH gene or the BAX gene of a cancer cell having a protein sequence that consists of a mutant part and a normal part;~~

~~b) includes at least one amino acid residue of the mutant part of the protein sequence;~~

~~c) comprises 0-10 amino acid residues from the carboxyl terminus of the normal part of the protein sequence preceding the amino terminus of the mutant part of the protein sequence and may further extend to the carboxyl terminus of the mutant part of the protein sequence, as determined by a new stop codon generated by the frameshift mutation; and~~

~~d) induces T cell responses, either in its full length form or after processing by an antigen presenting cell;~~

~~wherein the mutant part of the protein sequence has a sequence chosen from sequence identity nos. 1-459~~.

36. (Withdrawn) The peptide according to claim 35, wherein the peptide

arises from a frameshift mutation in the BAX gene.

37. (Cancelled)

38. (Withdrawn) The peptide according to claim 35, wherein the peptide arises from a frameshift mutation in the Human FADD/homologous ICE/CED-3-like protease gene.

39. (Withdrawn) The peptide according to claim 35, wherein the peptide arises from a frameshift mutation in the Human putative mismatch repair/binding protein (hMSH3) gene.

40. (Withdrawn) The peptide according to claim 35, wherein the peptide arises from a frameshift mutation in the Human neurofibromin (NF-1) gene.

41. (Withdrawn) The peptide according to claim 35, wherein the peptide arises from a frameshift mutation in the Human hMSH6 gene.

42. (Withdrawn) The peptide according to claim 35, wherein the peptide arises from a frameshift mutation in the Human transforming growth factor-beta induced gene product (BIGH3).

43. (Withdrawn) The peptide according to claim 35, wherein the peptide arises from a frameshift mutation in the Human protein-tyrosine kinase (JAK1) gene.

44. (Withdrawn) The peptide according to claim 35, wherein the peptide arises from a frameshift mutation in the Human protein-tyrosine kinase (JAK3) gene.

45. (Withdrawn) The peptide according to claim 35, wherein the peptide arises from a frameshift mutation in the Human retinoblastoma related protein (p107) gene.

46. (Withdrawn) The peptide according to claim 35, wherein the peptide arises from a frameshift mutation in the Human malignant melanoma metastasis-suppressor (hKiSS-1) gene.

47. (Withdrawn) The peptide according to claim 35, wherein the peptide arises from a frameshift mutation in the Human cysteine protease (ICE rel-III) gene.

48. (Withdrawn) The peptide according to claim 35, wherein the peptide arises from a frameshift mutation in the Human BRCA1-associated RING domain protein (BARD1) gene.

49. (Withdrawn) The peptide according to claim 35, wherein the peptide arises from a frameshift mutation in the Human DPC4 gene.

50. (Cancelled)

51. (Currently Amended) A ~~pharmaceutical~~ composition comprising a peptide according to ~~any of claims 35-50, and a pharmaceutically acceptable carrier or diluent~~ Claim 35 and a carrier or diluent therefor.

52. (Withdrawn) A cancer vaccine comprising a peptide according to any of claims 35-50, and a pharmaceutically acceptable carrier or diluent.

53. (Withdrawn) The use of a peptide according to claim 35, for the preparation of a pharmaceutical composition for the treatment or prophylaxis of cancer.

54. (Withdrawn) A method for vaccinating a human patient who is disposed to developing, or is afflicted with, cancer, comprising administering to the patient at least one peptide according to claim 35, one or more times, in an amount sufficient to induce specific T-cell immunity to the mutant protein or fragment thereof.

55. (Withdrawn) The method according to claim 54, wherein the amount of the peptide is in the range of 1 microgram (1 μg) to 1 gram (1 g) for each administration.

56. (Withdrawn) The method according to claim 55, wherein the amount of the peptide is in the range of 1 microgram (1 μg) to 1 milligram (1 mg) for each administration.

57. (Withdrawn) A method for treating a human patient afflicted with cancer comprising stimulating the patient *in vivo* or *ex vivo* with the peptide according to claim 35.

58. (Withdrawn) The method according to claim 57, wherein the amount of the peptide used is in the range of 1 microgram (1 μg) to 1 gram (1 g) for each administration.

59. (Withdrawn) The method according to claim 58, wherein the amount of the peptide used is in the range of 1 microgram (1 μg) to 1 milligram (1 mg) for each administration.

60. (Withdrawn) A pharmaceutical composition comprising a combination of at least one peptide according to claim 35, and at least one peptide according to International Application No. PCT/NO92/00032.

61. (Withdrawn) An isolated DNA sequence encoding the peptide described in claim 35.

62. (Withdrawn) The isolated DNA sequence according to claim 61, wherein the DNA sequence encodes a fragment of a protein having a sequence selected from the group consisting of seq. id. nos. 1-21, seq. id. no. 428, seq. id. no. 438, seq. id. nos. 456-458, and variants thereof.

63. (Withdrawn) The isolated DNA sequence according to claim 61, wherein the DNA sequence encodes a fragment of a protein having a sequence selected from the group consisting of seq. id. nos. 22-427, seq. id. nos. 429-437, seq. id. nos. 439-455, seq. id. no. 459, and variants thereof.

64. (Withdrawn) The use of a DNA sequence according to any of claims 61 or 62, for the preparation of a pharmaceutical composition for the treatment or prophylaxis of cancer.

65. (Withdrawn) A method for treating a human patient who is disposed to developing, or is afflicted with, cancer, comprising stimulating the patient *in vivo* or *ex vivo* with the DNA sequence according to any of claims 61-63.

66. (Withdrawn) A vector comprising the DNA sequence of claim 61.

67. (Withdrawn) The vector according to claim 66, wherein the vector is a plasmid or a viral vector.

68. (Withdrawn) The vector according to claim 66, wherein the vector is selected from the group consisting of an *E. coli* plasmid and a Listeria vector.

69. (Withdrawn) The vector according to claim 67, wherein the viral vector is

selected from the group consisting of an orthopox virus, a xanary virus, a capripox virus, a suipox virus, a vaccinia virus, a baculovirus, a human adenovirus, an SV40 virus and a bovine papilloma virus.

70. (Withdrawn) The use of the vector according to claim 66, for the preparation of a pharmaceutical composition for the treatment or prophylaxis of cancer.

71. (Withdrawn) A method of treating a human patient disposed to developing, or afflicted with, cancer, comprising stimulating the patient *in vivo* or *ex vivo* with a vector according to claim 66.

72. (Withdrawn) A method for vaccinating a human patient who is disposed to developing, or is afflicted with, cancer, comprising administering to the patient at least one peptide according to claims 36-50, one or more times, in an amount sufficient to induce a specific T-cell immunity to the mutant protein or fragment thereof.

73. (Withdrawn) A method for treating a human patient afflicted with cancer comprising stimulating the patient *in vivo* or *ex vivo* with a peptide according to any of claims 36-50.

74 (New): An isolated peptide consisting of Seq ID No. 17.

75 (New): An isolated peptide consisting of Seq ID No. 428.

76 (New): A method of stimulating the proliferation of human T cells, comprising the steps of: i) obtaining T cells from a human cancer patient and ii) contacting the T cells obtained in step i) with a peptide comprising Seq ID No. 428, said peptide being capable of inducing T cell proliferation, either in its full length form or after processing by an antigen-presenting cell.

77 (New): The method according to Claim 76, wherein the peptide used in step ii) comprises Seq ID No. 17.

78 (New): The method according to Claim 76, wherein the peptide used in step ii) is Seq ID No. 17.

79 (New): The method according to Claim 76, wherein the peptide used in step ii) is Seq ID No. 428.

80 (New): A composition comprising a peptide according to Claim 74 and a carrier or diluent therefor.

81 (New): A composition comprising a peptide according to Claim 75 and a carrier or diluent therefor.